Vancouver, BC, and Cambridge, MA, March 31, 2019 – Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, in association with its subsidiary Aegerion Pharmaceuticals, today announced its observance of World Lipodystrophy Day. World Lipodystrophy Day is an international campaign designed to raise awareness about the impact of living with lipodystrophy.
News
Recent Press Releases
March 31, 2019
March 14, 2019
Company achieves FY 2018 total net revenues of $130.4 million
FY 2018 operating expenses reduced by $27.2 million, or 18.4%
VANCOUVER, British Columbia, and Cambridge, MA, March 14, 2019 - Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the fourth quarter and year ended December 31, 2018.
June 25, 2018
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels
Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic disorder (HMD) by year-end